MAYNARD, Mass.--(BUSINESS WIRE)-- <\/p>\n
Allegro Diagnostics today announced the formation of its Clinical and Scientific Advisory Board. Allegro has developed a molecular testing platform that utilizes gene expression of normal epithelial cells in the respiratory tract to detect early signs of lung cancer. <\/p>\n
Our advisory board is comprised of some of the most respected and prolific clinicians, researchers and pioneers in the fields of pulmonary medicine, lung cancer and cancer diagnostics, said Michael D. Webb, President and Chief Executive Officer of Allegro Diagnostics. These individuals will play a central role in advising Allegro on its research and development efforts, as well as on the product development strategy for the BronchoGen genomic test, which is approaching commercialization. <\/p>\n
The members of the advisory board are: <\/p>\n
About the Allegro Platform <\/p>\n
Allegro Diagnostics molecular testing platform utilizes gene expression of normal epithelial cells in the respiratory tract to detect early signs of lung cancer. The field of injury principle on which the platform is based refers to the common molecular response that occurs throughout the respiratory tract in current and former smokers with lung cancer. These changes can be detected in a gene expression signature from non-malignant airway cells and indicate the presence of malignancy remotely in the lung. Allegro has applied this platform to generate multiple product candidates. <\/p>\n
About Allegro Diagnostics <\/p>\n
Allegro Diagnostics is a molecular diagnostics company focused on the development and commercialization of innovative genomic tests for the diagnosis, staging and informed treatment of lung cancer and other lung diseases. Allegro has developed a molecular testing platform that utilizes a genomic biomarker to detect early signs of lung cancer in current and former smokers. The companys lead product is the BronchoGen genomic test for use in combination with standard bronchoscopy for the diagnosis of lung cancer. http:\/\/www.allegrodx.com<\/a> <\/p>\n<\/p>\n See the original post: <\/p>\n Allegro Diagnostics Appoints Clinical and Scientific Advisory Board Comprised of Experts in Pulmonology, Lung Cancer ...<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" MAYNARD, Mass.--(BUSINESS WIRE)-- Allegro Diagnostics today announced the formation of its Clinical and Scientific Advisory Board. Allegro has developed a molecular testing platform that utilizes gene expression of normal epithelial cells in the respiratory tract to detect early signs of lung cancer Continue reading